

1 **Deciphering autoantibody landscape of systemic sclerosis through systems-based**  
2 **approach: insights from a B-cell depletion clinical trial**

3

4 Kazuki M Matsuda, MD, PhD,<sup>1</sup> Satoshi Ebata, MD, PhD,<sup>1</sup> Kazuhiro Iwadoh, MD,  
5 PhD,<sup>1</sup> Hirohito Kotani, MD, PhD,<sup>1</sup> Teruyoshi Hisamoto, MD, PhD,<sup>1</sup> Ai Kuzumi, MD,  
6 PhD,<sup>1</sup> Takemichi Fukasawa MD, PhD,<sup>1,2</sup> Asako Yoshizaki-Ogawa, MD, PhD,<sup>1</sup> Shinichi  
7 Sato, MD, PhD,<sup>1</sup> Ayumi Yoshizaki, MD, PhD<sup>1,2#</sup>

8

9 1. Department of Dermatology, The University of Tokyo Graduate School of Medicine,  
10 Tokyo, Japan

11 2. Department of Clinical Cannabinoid Research, The University of Tokyo Graduate  
12 School of Medicine, Tokyo, Japan

13

14 **# Corresponding author**

15 Ayumi Yoshizaki, MD, PhD

16 Department of Dermatology and Department of Clinical Cannabinoid Research, The

17 University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo,

18 Japan, 1138655

19 Phone: +81-3-3815-5411

20 ORCID: 0000-0002-8194-9140

21 E-mail: [ayuyoshi@me.com](mailto:ayuyoshi@me.com)

22 \_\_\_\_\_

23 **Abstract**

24           Systemic sclerosis (SSc) is a progressive fibrotic disorder with a high mortality  
25 rate, characterized by extensive autoantibody production. Despite recent advancements,  
26 effective treatments remain limited. Rituximab (RTX), a B-cell depleting agent, has  
27 shown promise in clinical trials. The DESIRES trial highlighted the reduction in  
28 modified Rodnan Skin Score (mRSS) and the association between serum  
29 immunoglobulin levels and RTX responsiveness. We employed proteome-wide  
30 autoantibody screening (PWAS) using wet protein arrays (WPAs) that display 13,455  
31 human autoantigens to analyze serum samples from SSc patients in the DESIRES trial  
32 and age- and sex-matched healthy controls (HCs). As a result, the sum of autoantibody  
33 levels (SAL) was significantly higher in SSc patients compared to HCs. High  
34 responders (HRs) to RTX showed a greater initial SAL and significant reductions  
35 post-treatment, unlike low responders (LRs). Machine learning identified specific  
36 autoantibodies linked to disease status, and 58 autoantibodies were identified as  
37 clinically relevant. Some of those autoantibodies targeted membrane proteins including  
38 G protein-coupled receptors, associated with better differentiation between HRs and  
39 LRs. Our findings underscore the significance of autoantibodies in SSc pathogenesis  
40 and their potential role in predicting RTX responsiveness. This comprehensive

41 autoantibody profiling could enhance diagnostic and therapeutic strategies, and

42 moreover, better understanding of the pathophysiology of SSc.

43

## 44 **Introduction**

45           Systemic sclerosis (SSc) is a progressive fibrotic disorder that affects both the  
46 skin and internal organs.<sup>1</sup> Among connective tissue diseases, it has the poorest  
47 prognosis, with an approximate 30% mortality rate within ten years.<sup>2</sup> Historically,  
48 treatment options for SSc have been limited. While the exact cause of SSc remains  
49 unclear, increasing evidence indicates that B cells play a significant role in the  
50 pathogenesis.<sup>3-5</sup> They contribute by producing autoantibodies, secreting unique  
51 cytokines, and activating other immune cells. Reflecting this understanding, various  
52 B-cell targeting therapeutic modalities, monoclonal antibodies,<sup>6-8</sup> Bruton's tyrosine  
53 kinase inhibitors,<sup>9</sup> and chimeric antigen receptor (CAR) T-cell therapies,<sup>10-12</sup> are  
54 emerging as promising treatments for SSc.

55           Rituximab (RTX) is a chimeric monoclonal antibody that depletes circulating  
56 B cells by targeting the B-cell specific antigen CD20. Previously, we conducted a  
57 double-blind, investigator-initiated, randomized, placebo-controlled trial, or the  
58 DESIRES trial,<sup>13</sup> which demonstrated significant superiority of RTX over placebo by  
59 the absolute reduction of modified Rodnan Skin Score (mRSS) 24 weeks after initiation  
60 of the study period. The open-label extension of this trial also revealed the long-term

61 efficacy and safety of RTX on SSc,<sup>14</sup> as well as the association between decrease in  
62 serum immunoglobulins and greater clinical response to RTX.<sup>15</sup>

63         The emergence of autoantibodies is a prominent feature of SSc, highlighting its  
64 nature as an autoimmune disorder. Anti-nuclear antibodies (ANAs), detected through  
65 indirect immunofluorescence on HEp-2 cells, are present in more than 90% of patients  
66 with SSc.<sup>16</sup> Several ANAs are specific to SSc or are closely associated with distinct  
67 clinical subsets. For instance, anti-topoisomerase I antibodies (ATA) are strongly linked  
68 to diffuse skin sclerosis and severe interstitial lung disease (ILD), while anti-centromere  
69 antibodies (ACA) are primarily associated with limited skin and lung involvement.<sup>17</sup>  
70 However, the pathogenicity of these ANAs is debated, as they cannot reach their targets  
71 across the plasma and nuclear membranes *in vivo*. Additionally, the DESIRES trials  
72 revealed that serum ATA levels did not decrease,<sup>13,14</sup> indicating that the relationship  
73 between serum immunoglobulin levels and responsiveness to RTX cannot be explained  
74 by ATA levels.

75         Herein, we employed our original technique for proteome-wide autoantibody  
76 screening (PWAS) using wet protein arrays (WPAs) that cover approximately 90% of  
77 the human transcriptome.<sup>18,19</sup> This technique has previously been used to develop  
78 multiplex measurements for disease-related autoantibodies,<sup>20,21</sup> identify clinically

79 relevant novel autoantibodies,<sup>22,23</sup> and investigate inter- and intra-molecular epitope  
80 spreading during the disease course. We applied PWAS to serum samples from SSc  
81 patients who participated in the DESIRES trial, as well as sex- and age-matched healthy  
82 controls (HCs). Our aim was to elucidate the autoantibody landscape in SSc and  
83 investigate clusters of autoantibodies that contribute to the reduction of serum  
84 immunoglobulin levels associated with a good response to RTX in SSc patients. This  
85 research seeks to identify novel biomarkers and gain a better understanding of the  
86 pathogenesis of SSc.

## 87 **Results**

### 88 *Subjects*

89           In the DESIRES trial (NCT04274257), a total of 56 individuals diagnosed with  
90 SSc were evenly randomized into two groups: 28 received RTX and 28 received a  
91 placebo.<sup>13</sup> Serum samples were collected at the start and after 24 weeks of treatment  
92 from participants who completed the term. These samples were reacted with WPAs for  
93 PWAS (**Figure 1A**). After excluding samples that were not suitable for PWAS, such as  
94 those containing anti-GST-tag antibodies, the study proceeded with 24 patients in the  
95 RTX group and 21 patients in the placebo group. The baseline characteristics of the two  
96 groups were comparable (**Table 1**). An equal number of age- and sex-matched healthy  
97 controls (HCs) were also included in the study (**Figure 1B**).

98

### 99 *The sum of autoantibody levels*

100           We defined the sum of autoantibody levels (SAL) as the total serum  
101 concentration of all autoantibodies assessed in our PWAS. SAL was significantly higher  
102 in SSc patients compared to HCs at the baseline ( $P < 0.0001$ ; **Figure 1C**). Subsequently,  
103 we categorized the RTX treatment group into two subgroups based on their response to  
104 treatment (**Figure 1D**): high responders (HRs;  $n = 11$ ) and low responders (LRs;  $n = 13$ ).



105 Initially, SAL was significantly greater in the HR group compared to the LR group ( $P <$   
106  $0.05$ ; **Figure 1E**). Additionally, SAL levels decreased significantly from week 0 to  
107 week 24 in the HR group ( $P < 0.05$ ), whereas changes in the LR group were not  
108 statistically significant. This pattern persisted across all age groups (**Extended Figure**  
109 **1A**). In contrast, serum levels of well-known SSc-related autoantibodies, including  
110 anti-topoisomerase I antibodies (ATA), anti-centromere antibodies (ACA), and  
111 anti-RNA polymerase III antibodies (ARA), did not follow this trend, as observed both  
112 in clinical-standard ELISA tests (**Figure 1F**) and in our PWAS (**Extended Figure 1B**).

113

#### 114 *Machine learning*

115 To determine which autoantibodies were driving the association between the  
116 SAL and disease status, we firstly utilized nine machine learning frameworks. Notably,  
117 Lasso regression, Ridge regression, SVM with normalization, XGBoost, and LightGBM  
118 achieved an area under the receiver-operator characteristics curve (ROC-AUC)  
119 exceeding 0.96, demonstrating an almost perfect ability to distinguish between SSc  
120 patients and HCs (**Table 2**). We identified the top 10 features in these six models  
121 (**Extended Figure 2A**), examined their inclusion relationships (**Extended Figure 2B**),  
122 and explored the prevalence of highlighted autoantibodies across a broader range of

123 human disorders using the aUToAntiBody Comprehensive Database (UT-ABCD).<sup>24</sup>  
124 Most of these autoantibodies were found to be non-specifically elevated in various  
125 pathological conditions, except for well-known SSc-specific autoantibodies such as  
126 ATA and ARA (**Extended Figure 2C**). Attempts to distinguish between HRs and LRs  
127 based on pre-treatment autoantibody profiles did not yield satisfactory precision  
128 (**Extended Table 1**).

129

### 130 *Investigating clinically relevant autoantibodies*

131 We next sought to identify autoantibodies significantly associated with the  
132 clinical features of SSc using the trial data that included longitudinal changes. Initially,  
133 we selected autoantibodies that were significantly elevated in SSc patients compared to  
134 HCs at baseline (**Figure 2A**). Next, we chose autoantibodies that were significantly  
135 higher in HRs compared to LRs (**Figure 2B**). Lastly, we focused on autoantibodies  
136 whose serum concentrations significantly decreased from week 0 to week 24 in HRs  
137 (**Figure 2C**). As a result, 58 autoantibodies were identified as candidates for clinically  
138 relevant autoantibodies in SSc (**Figure 2D**). Principal component analysis (PCA)  
139 indicated that these 58 autoantibodies appear to distinguish HRs at week 0 within the  
140 dataset (**Figure 2E**). The sum of the serum levels of these autoantibodies displayed a

141 pattern like SAL, but in a more pronounced manner (**Figure 2F**). Consistently,  
142 ROC-AUC analysis showed that these 58 autoantibodies provide better differentiation  
143 between SSc patients and HCs compared to the complete autoantibody profile (**Figure**  
144 **2G**), and moreover, distinguish between HRs and LRs with nearly perfect precision  
145 (**Figure 2H**).

146

#### 147 *Profiling candidate autoantibodies*

148 To explore the molecular features of the human proteins targeted by the  
149 identified candidate autoantibodies, we conducted gene ontology enrichment analyses  
150 utilizing Metascape.<sup>25</sup> Notably, whereas established SSc-related autoantibodies  
151 primarily target intracellular antigens, our findings emphasized membrane proteins  
152 associated with processes such as "import across plasma membrane" and "peptide G  
153 protein-coupled receptors (GPCRs)" (**Figure 3A**). There were four autoantibodies  
154 linked to each of the processes "import across plasma membrane" and "peptide GPCRs"  
155 (**Figure 3B**). Autoantibodies associated with plasma membrane import included those  
156 targeting presenilin 1 (PSEN1), solute carrier family 22 member 2 (SLC22A2), transient  
157 receptor potential cation channel subfamily V member 5 (TRPV5), and solute carrier  
158 family 46 member 1 (SLC46A1; **Figure 3C**). The group related to peptide GPCRs

159 comprised autoantibodies against chemokine receptor 8 (CCR8), formyl peptide  
160 receptor 1 (FPR1), melanocortin 1 receptor (MC1R), and G protein-coupled receptor 63  
161 (GPR63; **Figure 3E**). The associations between each autoantibody and the clinical  
162 characteristics of SSc were detailed in **Figures 3D and 3F**, which highlighted positive  
163 correlation between anti-TRPV5 and anti-CCR8 antibody levels and mRSS, as well as  
164 negative correlation between anti-FPR1 antibody levels and forced lung capacity. We  
165 also investigated the distribution of these highlighted autoantibodies in a broader  
166 population, utilizing UT-ABCD. As a result, all the items were not specific to SSc  
167 (**Extended Figure 3**).

168         The tissue specificity of the highlighted autoantigens was investigated using  
169 publicly available databases. Analysis of multiple human tissues through bulk RNA  
170 sequencing data from the Human Protein Atlas<sup>26</sup> revealed that *CCR8* and *FPR1* are  
171 enriched in bone marrow and lymphoid tissues (**Extended Figure 4, A and B**).  
172 Single-cell RNA sequencing data from the Tabula Sapiens project<sup>27</sup> showed that *CCR8*  
173 expression is enhanced in regulatory T cells (Tregs; **Extended Figure 4C**), while *FPR1*  
174 expression is elevated in neutrophils (**Extended Figure 4D**). Meanwhile, *TRPV5*  
175 expression was localized in the kidney, and *MC1R* expression appeared to be relatively  
176 ubiquitous across different tissues.

177

178 *Weighted correlation network analysis*

179           We utilized weighted correlated network analysis (WGCNA)<sup>28</sup> to delve deeper  
180 into the correlations between autoantibodies in SSc. Our study included 135 specimens  
181 from SSc patients at weeks 0 and 24, as well as HCs. We constructed a correlation  
182 network for all autoantibodies evaluated in our PWAS and identified 57 distinct  
183 modules (**Figure 4A**). The "turquoise" module, which contained ATA, also included  
184 half of the candidate autoantibodies: anti-TRPV5, CCR8, MC1R, and GPR63  
185 antibodies (**Figure 4B**). The "darkmagenta" module included ARA. The "tan" module  
186 included ACA. The other candidate autoantibodies did not appear in either the  
187 "darkmagenta" or "tan" modules. We also conducted gene ontology analyses on the  
188 gene lists encoding proteins targeted by autoantibodies within these three modules  
189 (**Extended Table 2**). The Enrichment score was the highest for "mitochondrion  
190 organization" in the "turquoise" module (**Figure 4C**). The enrichment scores for  
191 "regulation of cellular response to stress" were highest in the "turquoise" module,  
192 moderate in the "darkmagenta" module, and lowest in the "tan" module. This pattern  
193 aligns with the clinical severity associated with ATA, ARA, and ACA.

194           We also reviewed the associations between each module and clinical traits  
195   **(Figure 4D)**. The "turquoise" module was positively linked to ATA, a higher modified  
196   Rodnan Skin Score (mRSS) – the primary endpoint of the DESIRES trial – as well as to  
197   lower patient-reported quality of life, evidenced by higher Health Assessment  
198   Questionnaire (HAQ) scores and lower 36-Item Short Form Health Survey (SF-36)  
199   scores. The "darkmagenta" module was associated with ARA positivity and higher  
200   forced vital capacity of the lungs, indicating a lower degree of ILD. The "tan" module  
201   was correlated with the ACA profile but did not show any significant associations with  
202   other clinical traits  
203

204 **Discussion**

205           In this study, we applied our original PWAS technique subjecting serum  
206 samples from SSc patients who participated in the DESIRES trial, along with sex and  
207 age-matched HCs. Our findings revealed a significant elevation in the overall amount of  
208 autoantibodies in SSc patients compared to HCs (**Figure 1**). We identified 58  
209 autoantibodies as clinically relevant candidates in SSc, which showed a strong response  
210 to B-cell depletion therapy (**Figure 2**). Gene ontology analysis highlighted  
211 autoantibodies targeting membranous proteins, including transmembrane transporters  
212 and GPCRs (**Figure 3**). Most of them were clustered in the same module identified by  
213 WGCNA, which was significantly associated with ATA positivity, higher mRSS, and  
214 lower patient-reported quality of life (**Figure 4**). We demonstrated the nearly perfect  
215 distinction between SSc and HC samples achieved through machine learning (**Table 2**),  
216 and SSc patients who show good response to RTX treatment engaging the clinically  
217 relevant autoantibodies highlighted in our analyses (**Figure 2H**). These results  
218 underscore the effectiveness of our integrating systems-based comprehensive  
219 autoantibody screening and bioinformatic analyses, which could be called as  
220 "autoantigenomics."<sup>29</sup>

221 Our machine learning analysis confirmed the prominence of well-known  
222 SSc-specific ANAs such as ATA and ARA (**Extended Figure 2**). However, these  
223 autoantibodies did not exhibit longitudinal changes during the clinical trial nor  
224 differences between HRs and LRs to RTX treatment (**Figure 1F and Extended Figure**  
225 **1B**), consistent with our previous findings.<sup>13,14</sup> In contrast, we observed that changes in  
226 the overall levels of autoantibodies were significantly correlated with RTX efficacy  
227 (**Figure 1, C and E**). This discrepancy led us to investigate autoantibodies that exhibit  
228 significant associations with the time course and drug response to RTX therapy. While  
229 predictive factors for RTX responsiveness have been limited to clinical indicators such  
230 as CD19-positive cell counts, mRSS, and serum levels of SP-D,<sup>30</sup> the clinically relevant  
231 autoantibodies we identified were able to discriminate between HRs and LRs with high  
232 accuracy (**Figure 2H**). Interestingly, some of these autoantibodies targeted membranous  
233 antigens (**Figure 3**), suggesting that they are not only useful as biomarkers but also  
234 could play a direct role in the pathogenesis of SSc.

235 Accumulating evidence has unveiled the relevance of autoantibodies targeting  
236 GPCRs in immune-related human disorders, including SSc.<sup>31,32</sup> Notably, previous  
237 studies have indicated the relationship between GPCRs targeted by the candidate  
238 autoantibodies and the pathogenesis of SSc. CCR8 is primarily expressed on Tregs



239 **(Extended Figure 4C)**, which suppress autoimmune responses.<sup>33</sup> CC Chemokine 1  
240 (CCL1) acts as a chemoattractant, recruiting Tregs to peripheral tissues by binding to  
241 CCR8.<sup>34</sup> While direct evidence linking the CCR8-CCL1 axis to SSc pathogenesis is  
242 lacking, blocking CCR8 could exacerbate autoimmune responses in SSc by inhibiting  
243 Treg homing to target tissues. FPR1, which is abundantly expressed on neutrophils  
244 **(Extended Figure 4D)**, induces inflammation when bound by its cognate ligands.<sup>35</sup>  
245 One such endogenous agonist is N-formyl-methionine (fMet), a mitochondrial  
246 protein-derived molecule that serves as a damage-associated molecular pattern.<sup>36</sup> Lurley  
247 R et al. have shown in SSc, elevated serum fMet levels and fMet-induced activation of  
248 neutrophils through FPR1-dependent mechanisms.<sup>37</sup> Consistent with these findings, our  
249 enrichment analysis highlighted mitochondrion-associated antigens targeted by  
250 autoantibodies in SSc **(Figure 4C)**, suggesting mitochondrial destruction, which has  
251 also been reported in other autoimmune conditions such as systemic lupus  
252 erythematosus and rheumatoid arthritis. MC1R is expressed on various cell types  
253 **(Extended Figure 4B)**, including melanocytes, inflammatory cells, endothelial cells,<sup>38</sup>  
254 and skin fibroblasts from SSc patients.<sup>39</sup> Its endogenous ligand,  
255  $\alpha$ -melanocyte-stimulating hormone, induces melanin production in melanocytes and  
256 promotes anti-inflammatory responses, such as inhibition of nuclear factor- $\kappa$ B and

257 suppression of pro-inflammatory cytokines.<sup>40</sup> Kondo M et al. demonstrated that  
258 dersimelagon (MT-7117), an oral MC1R agonist, has favorable effects on inflammation,  
259 vascular dysfunction, and fibrosis, which are key pathologies in preclinical SSc  
260 models.<sup>41</sup> This prompted a phase 2 clinical trial to evaluate the efficacy and tolerability  
261 of MT-7117 in patients with early, progressive diffuse cutaneous SSc (NCT04440592).  
262 Collectively, accumulating experimental and clinical evidence suggests that modulating  
263 these GPCRs, either through stimulation or blockade, could potentially alter SSc disease  
264 severity.

265         Meanwhile, it is important to note that the serum levels of the candidate  
266 autoantibodies we identified were relatively modest compared to conventional  
267 SSc-specific autoantibodies like ATA (**Extended Figure 1B**). Moreover, the presence  
268 of these candidate autoantibodies did not appear to be specific to SSc, as indicated by  
269 data from UT-ABCD (**Extended Figure 3A and 3B**). These suggest that the  
270 pathogenesis of SSc may not be attributed to a single unique autoantibody that shows  
271 strong cross-reactivity with conventional SSc-specific autoantibodies, but rather to a  
272 collaboration of multiple autoantibodies. This hypothesis aligns with several  
273 observations that suggest that SSc is a multifactorial disease, involving a combination  
274 of various autoantibodies and other factors rather than a single causative factor. First,

275 genome-wide association studies have not identified a single gene mutation strongly  
276 linked to SSc.<sup>42</sup> Second, the disease concordance in twins is modest and similar  
277 between monozygotic and dizygotic twins, further supporting the notion that SSc is not  
278 caused only by genetic factors.<sup>43</sup> Finally, and most importantly, the clinical  
279 manifestations of SSc are highly heterogeneous.<sup>1</sup>

280           Alternatively, a cluster of several autoantibodies, with combinations that vary  
281 among patients, might explain the heterogeneity of clinical manifestations in SSc.<sup>44</sup>  
282 Co-localization of ATA and candidate autoantibodies within the same module identified  
283 by WGCNA, as well as the distribution of ATA, ARA, and ACA among different  
284 modules (**Figure 4**), support this hypothesis. Such clustering of autoantibodies might  
285 result from cross reaction with a single specific exogenous antigen such as viruses,<sup>45,46</sup>  
286 or intermolecular epitope spreading, a phenomenon we have recently demonstrated to  
287 be involved in SSc progression using the same WPA system.<sup>47</sup> Further research is  
288 needed to unravel the relationships among these autoantibodies and their collective  
289 contribution to SSc development. This research should include comparisons of  
290 structural similarity and epitope mapping for the relevant antigens, and longitudinal  
291 serological monitoring in each case. Understanding these interactions will be crucial for

292 comprehensively elucidating the mechanisms underlying the autoimmune aspect of SSc  
293 and potentially identifying new therapeutic targets.

294 Our study has several notable strengths. Firstly, the data presented is derived  
295 from a prospective, randomized, placebo-controlled clinical trial, which includes two  
296 time points (before and after RTX therapy). This adherence to good clinical practice  
297 ensures high data accuracy. Secondly, the use of the wheat-germ *in vitro* protein  
298 synthesis system and the manipulation technique for WPAs enabled high-throughput  
299 expression of a variety of human proteins, including membranous proteins, on a single  
300 platform.<sup>18</sup> As a result, our autoantibody measurement could encompass a wider range  
301 of antigens at an almost proteome-wide level, allowing for the application of  
302 omics-based bioinformatics approaches to interpret the data.<sup>24</sup> Meanwhile, one major  
303 limitation is the lack of functional assays both *in vitro* and *in vivo*. Further investigation  
304 is needed to determine whether the candidate autoantibodies we identified act as  
305 agonists or antagonists to their target proteins, and whether they influence the  
306 pathophysiology of SSc. Moreover, the value of autoantibodies we identified for  
307 predicting treatment response to RTX should be validated in external cohorts in  
308 real-world clinical settings.  
309

310 **References**

- 311 1. Allanore, Y. *et al.* Systemic sclerosis. *Nat. Rev. Dis. Prim.* **1**, 1–21 (2015).
- 312 2. Rubio-Rivas, M., Royo, C., Simeón, C. P., Corbella, X. & Fonollosa, V.
- 313 Mortality and survival in systemic sclerosis: Systematic review and
- 314 meta-analysis. *Semin. Arthritis Rheum.* **44**, 208–219 (2014).
- 315 3. Hasegawa, M. *et al.* B-lymphocyte depletion reduces skin fibrosis and
- 316 autoimmunity in the tight-skin mouse model for systemic sclerosis. *Am. J. Pathol.*
- 317 **169**, 954–66 (2006).
- 318 4. Numajiri, H. *et al.* B Cell Depletion Inhibits Fibrosis via Suppression of
- 319 Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis.
- 320 *Arthritis Rheumatol.* **73**, 2086–2095 (2021).
- 321 5. Fukasawa, T. *et al.* Single-cell-level protein analysis revealing the roles of
- 322 autoantigen-reactive B lymphocytes in autoimmune disease and the murine
- 323 model. doi:10.7554/eLife.
- 324 6. Daoussis, D. *et al.* A multicenter, open-label, comparative study of B-cell
- 325 depletion therapy with Rituximab for systemic sclerosis-associated interstitial
- 326 lung disease. *Semin. Arthritis Rheum.* **46**, 625–631 (2017).

- 327 7. Sircar, G., Goswami, R. P., Sircar, D., Ghosh, A. & Ghosh, P. Intravenous  
328 cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma  
329 lung disease: Open label, randomized, controlled trial. *Rheumatol. (United*  
330 *Kingdom)* **57**, 2106–2113 (2018).
- 331 8. Ebata, S. *et al.* Rituximab therapy is more effective than cyclophosphamide  
332 therapy for Japanese patients with anti-topoisomerase I-positive systemic  
333 sclerosis-associated interstitial lung disease. *J. Dermatol.* **46**, 1006–1013 (2019).
- 334 9. Einhaus, J. *et al.* Inhibition of effector B cells by ibrutinib in systemic sclerosis.  
335 *Arthritis Res. Ther.* **22**, 1–8 (2020).
- 336 10. Bergmann, C. *et al.* Treatment of a patient with severe systemic sclerosis (SSc)  
337 using CD19-targeted CAR T cells. *Ann. Rheum. Dis.* **82**, 1117–1120 (2023).
- 338 11. Merkt, W. *et al.* Third-generation CD19.CAR-T cell-containing combination  
339 therapy in Scl70+ systemic sclerosis. *Ann. Rheum. Dis.* **83**, 543 LP – 546 (2024).
- 340 12. Fabian, M. *et al.* CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case  
341 Series with Follow-up. *N. Engl. J. Med.* **390**, 687–700 (2024).
- 342 13. Ebata, S. *et al.* Safety and efficacy of rituximab in systemic sclerosis  
343 (DESIREs): a double-blind, investigator-initiated, randomised,  
344 placebo-controlled trial. *Lancet Rheumatol.* **3**, e489–e497 (2021).

- 345 14. Ebata, S. *et al.* Safety and efficacy of rituximab in systemic sclerosis  
346 (DESIREs): open-label extension of a double-blind, investigators-initiated,  
347 randomised, placebo-controlled trial. *Lancet Rheumatol.* **4**, e546–e555 (2022).
- 348 15. Kuzumi, A. *et al.* Long-term Outcomes After Rituximab Treatment for Patients  
349 With Systemic Sclerosis: Follow-up of the DESIREs Trial With a Focus on  
350 Serum Immunoglobulin Levels. *JAMA Dermatology* **159**, 374–383 (2023).
- 351 16. Okano, Y. Antinuclear antibody in systemic sclerosis (scleroderma). *Rheum Dis*  
352 *Clin North Am* **22**, 709–35 (1996).
- 353 17. Nihtyanova, S. I. & Denton, C. P. Autoantibodies as predictive tools in systemic  
354 sclerosis. *Nat. Rev. Rheumatol.* **6**, 112–116 (2010).
- 355 18. Goshima, N. *et al.* Human protein factory for converting the transcriptome into  
356 an in vitro-expressed proteome. *Nat. Methods* **5**, 1011–1017 (2008).
- 357 19. Fukuda, E. *et al.* Identification and characterization of the antigen recognized by  
358 the germ cell mAb TRA98 using a human comprehensive wet protein array.  
359 *Genes to Cells* **26**, 180–189 (2021).
- 360 20. Matsuda, K. M. *et al.* Autoantibody Landscape Revealed by Wet Protein  
361 Array: Sum of Autoantibody Levels Reflects Disease Status. *Front. Immunol.*  
362 **13**, 1–14 (2022).

- 363 21. Kuzumi, A. *et al.* Comprehensive autoantibody profiling in systemic  
364 autoimmunity by a highly-sensitive multiplex protein array. *Front. Immunol.* **14**,  
365 (2023).
- 366 22. Matsuda, K. M., Kotani, H., Yamaguchi, K., Okumura, T. & Fukuda, E.  
367 Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis  
368 revealed by proteome-wide autoantibody screening. *J. Autoimmun.* **135**, 102995  
369 (2023).
- 370 23. Matsuda, K. M. *et al.* Autoantibodies to nuclear valosin-containing protein-like  
371 protein: systemic sclerosis-specific antibodies revealed by in vitro human  
372 proteome. *Rheumatology (Oxford)*. (2024) doi:10.1093/rheumatology/keae063.
- 373 24. Matsuda, K. M. *et al.* Proteome-wide autoantibody screening and holistic  
374 autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape.  
375 *medRxiv* 2024.06.07.24308592 (2024).
- 376 25. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis  
377 of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
- 378 26. Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by  
379 genome-wide integration of transcriptomics and antibody-based proteomics. *Mol.*  
380 *Cell. Proteomics* **13**, 397–406 (2014).



- 381 27. The Tabula Sapiens Consortium. The Tabula Sapiens: A multiple-organ,  
382 single-cell transcriptomic atlas of humans. *Science* (80-. ). **376**, eabl4896 (2022).
- 383 28. Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation  
384 network analysis. *BMC Bioinformatics* **9**, (2008).
- 385 29. Moritz, C. P. *et al.* Autoantigenomics: Holistic characterization of autoantigen  
386 repertoires for a better understanding of autoimmune diseases. *Autoimmun. Rev.*  
387 **19**, 102450 (2020).
- 388 30. Matsuda, K. M. *et al.* Development of a prediction model of treatment response  
389 in patients with cutaneous arteritis□: Insights from a cohort of 33 patients. *J.*  
390 *Dermatol.* **48**, 1021–1026 (2021).
- 391 31. Cabral-Marques, O. *et al.* GPCR-specific autoantibody signatures are associated  
392 with physiological and pathological immune homeostasis. *Nat. Commun.* **9**, 5224  
393 (2018).
- 394 32. Akbarzadeh, R., Müller, A., Humrich, J. Y. & Riemekasten, G. When natural  
395 antibodies become pathogenic: autoantibodies targeted against G  
396 protein-coupled receptors in the pathogenesis of systemic sclerosis. *Front.*  
397 *Immunol.* **14**, 1213804 (2023).

- 398 33. Barsheshet, Y. *et al.* CCR8+FOXP3+ Treg cells as master drivers of immune  
399 regulation. *Proc. Natl. Acad. Sci.* **114**, 6086–6091 (2017).
- 400 34. Tiffany, H. L. *et al.* Identification of CCR8: a human monocyte and thymus  
401 receptor for the CC chemokine I-309. *J. Exp. Med.* **186**, 165–170 (1997).
- 402 35. McDonald, B. *et al.* Intravascular Danger Signals Guide Neutrophils to Sites of  
403 Sterile Inflammation. *Science (80-. )*. **330**, 362–367 (2011).
- 404 36. Zhang, Q. *et al.* Circulating mitochondrial DAMPs cause inflammatory responses  
405 to injury. *Nature* **464**, 104–107 (2010).
- 406 37. Kuley, R. *et al.* N-Formyl Methionine Peptide- Mediated Neutrophil Activation  
407 in Systemic Sclerosis. *Front. Immunol.* **12**, 1–12 (2022).
- 408 38. Getting, S. J. Targeting melanocortin receptors as potential novel therapeutics.  
409 *Pharmacol. Ther.* **111**, 1–15 (2006).
- 410 39. Kokot, A. *et al.*  $\alpha$ -melanocyte-stimulating hormone suppresses  
411 bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse  
412 model of scleroderma: Melanocortin peptides as a novel treatment strategy for  
413 scleroderma? *Arthritis Rheum.* **60**, 592–603 (2009).
- 414 40. Wang, W., Guo, D.-Y., Lin, Y.-J. & Tao, Y.-X. Melanocortin Regulation of  
415 Inflammation. *Front. Endocrinol. (Lausanne)*. **10**, (2019).

- 416 41. Kondo, M. *et al.* Dersimelagon, a novel oral melanocortin 1 receptor agonist,  
417 demonstrates disease-modifying effects in preclinical models of systemic  
418 sclerosis. *Arthritis Res. Ther.* **24**, 1–17 (2022).
- 419 42. Ishikawa, Y. *et al.* GWAS for systemic sclerosis identifies six novel  
420 susceptibility loci including one in the Fc $\gamma$  receptor region. *Nat. Commun.* **15**,  
421 319 (2024).
- 422 43. Feghali-Bostwick, C., Medsger, T. A. J. & Wright, T. M. Analysis of systemic  
423 sclerosis in twins reveals low concordance for disease and high concordance  
424 for the presence of antinuclear antibodies. *Arthritis Rheum.* **48**, 1956–1963  
425 (2003).
- 426 44. Kuzumi, A., Norimatsu, Y. & Matsuda, K. M. Comprehensive autoantibody pro  
427 fi ling in systemic autoimmunity by a highly- sensitive multiplex protein array.  
428 1–14 (2023) doi:10.3389/fimmu.2023.1255540.
- 429 45. Lunardi, C. *et al.* Systemic sclerosis immunoglobulin G autoantibodies bind the  
430 human cytomegalovirus late protein UL94 and induce apoptosis in human  
431 endothelial cells. *Nat. Med.* **6**, 1183–1186 (2000).
- 432 46. Ohtsuka, T. & Yamazaki, S. Increased prevalence of human parvovirus B19  
433 DNA in systemic sclerosis skin. *Br. J. Dermatol.* **150**, 1091–1095 (2004).

- 434 47. Kotani, H. *et al.* Diversity and epitope spreading of anti-RNA polymerase □  
435 antibodies in systemic sclerosis: a potential biomarker for skin and lung  
436 involvement. *Arthritis Rheumatol.* **in press**, (2024).
- 437 48. Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric Preprocessing  
438 for Parametric Causal Inference. *J. Stat. Softw.* **42**, 1–28 (2011).
- 439 49. Khanna, D. *et al.* Standardization of the modified Rodnan skin score for use in  
440 clinical trials of systemic sclerosis. *J. Scleroderma Relat. Disord.* **2**, 11–8 (2017).
- 441 50. Khanna, D. *et al.* Minimally important difference in diffuse systemic sclerosis:  
442 results from the D-penicillamine study. *Ann. Rheum. Dis.* **65**, 1325–1329 (2006).
- 443
- 444

445 **Acknowledgements**

446 We thank Ms. Maiko Enomoto and her colleagues for their secretarial work.

447 We appreciate K. Yamaguchi, T. Okumura, C. Ono, A. Sato, A. Miya, and N. Goshima

448 from ProteoBridge Corporation for preparing the WPs. We also acknowledge R.

449 Uchino, Y. Murakami, and H. Matsunaka from TOKIWA Pharmaceuticals Co. Ltd. for

450 providing technical assistance with autoantibody measurement.

451 **Author Contributions**

452           KM Matsuda primarily engaged in autoantibody measurement, clinical data  
453 collection, data analysis, visualization, and writing the first draft of the manuscript. K  
454 Iwadoh participated in machine learning analysis. S Ebata was primarily engaged in the  
455 management of SSc patients participated in the DESIRES trial. H Kotani, A Kuzumi, T  
456 Fukasawa, A Yoshizaki-Ogawa took part in the sample collection of SSc. S Sato  
457 conceptualized and supervised the study. A Yoshizaki conceptualized, launched, and  
458 supervised this study, and was involved in revising the manuscript.  
459

460 **Conflict-of-interest statement**

461 T Fukasawa and A Yoshizaki belong to the Social Cooperation Program,  
462 Department of Clinical Cannabinoid Research, The University of Tokyo Graduate  
463 School of Medicine, Tokyo, Japan, supported by Japan Cosmetic Association and Japan  
464 Federation of Medium and Small Enterprise Organizations. The remaining authors  
465 declare that the research was conducted in the absence of any commercial or financial  
466 relationships that could be construed as a potential conflict of interest.  
467

468 **Funding**

469           The DESIRES trial was funded by Japan Agency for Medical Research and  
470 Development (AMED, grant number JP19ek0109299) and Zenyaku Kogyo Co, Ltd,  
471 Japan. As the trial was an investigator-initiated clinical trial, the funders were not  
472 involved in any way in the designing, analysis, interpretation, or drafting of the study.  
473



474 **Methods**

475 *Study Design*

476 The study design for the DESIRES trial has been previously reported  
477 (NCT04274257).<sup>13</sup> The full protocol of the trial is available at  
478 <https://clinicaltrials.gov/study/NCT04274257>. Briefly, the DESIRES trial was a  
479 randomized, double-blind, placebo-controlled trial of 24 weeks. The primary endpoint  
480 of the double-blind phase was the absolute change in mRSS 24 weeks after 13  
481 intervention initiation compared to the baseline. In total, 56 patients were randomized to  
482 receive either intravenous rituximab (375 mg/m<sup>2</sup>) or matching placebo once per week  
483 for 4 weeks, based on the allocation factors of 4 disease duration ( $\leq 6$  years or  $> 6$  years),  
484 mRSS ( $\geq 20$  or  $< 20$ ), and concomitant ILD (present or absent) by the minimization  
485 method. Of these, 49 patients completed the double-blind phase. Serum samples were  
486 collected and served for PWAS at the beginning and the end of the double-blind phase  
487 (**Fig. 1A**). After excluding 4 cases due to their serum unsuitable for PWAS, data of 45  
488 patients were included in our analysis. Age and sex matched HCs were selected from a  
489 cohort of healthcare providers on annual checkups without any medical history (**Fig.**  
490 **1B**), using “matchIt” R package.<sup>48</sup> This study was approved by the ethics committee of  
491 the University of Tokyo Graduate School of Medicine and conducted in accordance

492 with the Declaration of Helsinki. Written informed consent was obtained from all  
493 patients.

494

#### 495 *Assessments*

496 Clinical and laboratory assessments were performed at baseline and at 24  
497 weeks after the first infusion of rituximab. Skin sclerosis was assessed by mRSS.<sup>49</sup>

498 Lung function was evaluated by pulmonary function tests. Serum levels of Krebs von  
499 den Lungen-6 (KL-6; normal range: 0-500 U/mL) and surfactant protein-D (SP-D;

500 normal range: 0-110 ng/mL), which are glycoproteins mainly produced by type II  
501 pneumocytes, were measured as established markers of ILD in patients with SSc.

502 Laboratory examinations included white blood cell count, lymphocyte count, the  
503 number of CD19<sup>+</sup> and CD20<sup>+</sup> cells, and serum levels of IgG (normal range: 700-1600

504 mg/dL), IgM (normal range: 40-250 mg/dL), and IgA (normal range: 70-400 mg/dL).

505 Patients with mRSS improvement of 7 or higher and 6 or lower were classified as HRs

506 and LRs, respectively, based on the previous study on minimally important differences

507 for mRSS.<sup>50</sup> This classification resulted in 16 high responders and 13 LRs (**Fig. 1C**).

508

#### 509 *Autoantibody measurement*

510 WPA s were arranged as previously described.<sup>20</sup> First, proteins were  
511 synthesized *in vitro* utilizing a wheat germ cell-free system from 13,455 clones of the  
512 HuPEX.<sup>18</sup> Second, synthesized proteins were plotted onto glass plates (Matsunami  
513 Glass, Osaka, Japan) in an array format by the affinity between the GST-tag added to  
514 the N-terminus of each protein and glutathione modified on the plates. The WPAs were  
515 treated with human serum diluted by 3:1000 in the reaction buffer containing 1x  
516 Synthetic block (Invitrogen), phosphate-buffered saline (PBS), and 0.1% Tween 20.  
517 Next, the WPAs were washed, and goat anti-Human IgG (H+L) Alexa Flour 647  
518 conjugate (Thermo Fisher Scientific, San Jose, CA, USA) diluted 1000-fold was added  
519 to the WPAs and reacted for 1 hour at room temperature. Finally, the WPAs were  
520 washed, air-dried, and fluorescent images were acquired using a fluorescence imager  
521 (Typhoon FLA 9500, Cytiva, Marlborough, MA, USA). Fluorescence images were  
522 analyzed to quantify serum levels of autoantibodies targeting each antigen, following  
523 the formula shown below:

524

$$Autoantibody\ level\ [AU] = \frac{F_{autoantigen} - F_{negative\ control}}{F_{positive\ control} - F_{negative\ control}} \times 100$$

525 *AU*: arbitrary unit

526  $F_{autoantigen}$ : fluorescent intensity of autoantigen spot

527  $F_{negative\ control}$  fluorescent intensity of negative control spot

528  $F_{positive\ control}$  fluorescent intensity of positive control spot

529

530 *Machine learning*

531 We applied supervised machine learning techniques using the Python code  
532 with the scikit-learn library to analyze the autoantibody measurement data. With the  
533 random forest model, decision trees were built and trained in parallel on subsets of  
534 sampled instances and features. Meanwhile, with the XGBoost model, decision trees  
535 were built sequentially to improve each other. The final prediction of the random forest  
536 was based on the majority of its decision trees, while that of XGBoost was derived from  
537 their weighted average. The performance of the classifiers was evaluated using the area  
538 under the operator-receiver characteristics curve (AUC), accuracy, precision, recall, and  
539 F1-score, with the higher the scores indicating the better classification performance. The  
540 accuracy is the ratio of the correct positive and negative prediction, the precision is the  
541 ratio of the correct positive prediction, the recall (or sensitivity) is the ratio of the  
542 correct positive prediction among all true positive instances, and F1-score is the  
543 harmonic mean of precision and sensitivity.

544

545 *WGCNA analysis*

546           The weighted gene co-expression network was constructed using the  
547 "WGCNA" R package.<sup>28</sup> We calculated each gene pair's Pearson correlation coefficient,  
548 measured how similarly their expressions were expressed, and created a correlation  
549 matrix. Scale-free topology requirements were used to compute the "soft" threshold  
550 power to build biologically meaningful scale-free networks. Based on the adjacency  
551 matrix, dynamic tree cuts and at least 100 genes per module were utilized to generate a  
552 topological overlap matrix for co-expression modules. In addition, we assessed gene  
553 significance, module membership, and correlated modules with clinical characteristics  
554 and mapped signature genes.

555

556 *Statistical analysis*

557           Fisher exact test was performed to compare categorical variables.  
558 Mann-Whitney U test or Wilcoxon signed-rank test as appropriate was performed to  
559 compare continuous variables. Spearman correlation test was used for correlation  
560 analysis. P values of < 0.05 were considered statistically significant. Gene Ontology  
561 Analysis using web-based tools targeted the list of the entry clones coding the  
562 differentially highlighted autoantigens was performed for gene-list enrichment analysis,

563 gene-disease association analysis, and transcriptional regulatory network analysis with

564 Metascape.<sup>25</sup> Data analyses were conducted using R (v4.2.1).

565

566 *Data visualization*

567 Box plots, scatter plots, hierarchical clustering, and correlation matrix were

568 visualized by using R (v4.2.1). Box plots were defined as follows: the middle line

569 corresponds to the median; the lower and upper hinges correspond to the first and third

570 quartiles; the upper whisker extends from the hinge to the largest value no further than

571 1.5 times the interquartile range (IQR) from the hinge; and the lower whisker extends

572 from the hinge to the smallest value at most 1.5 times the IQR of the hinge.

573

## Figure legends

**Figure 1. Overview of the study.** (A) The study design of the DESIRES trial. (B) The flow chart of sample acquisition in the present study. (C) The sum of autoantibody levels (SAL) in SSc at the baseline and HCs. (D) Absolute change of mRSS in SSc patients during the DESIREs trial. HR: high responder, LR: low responder. (E) SAL before and after the study period of the DESIRES trial by the treatment arm. (F) Serum levels of SSc-related autoantibodies before and after the study period of the DESIRES trial by the treatment arm. ATA: anti-topoisomerase I antibody, ACA: anti-centromere antibody, ARA: anti-RNA polymerase III antibody. \*:  $P < 0.05$ , \*\*\*\*\*:  $P < 0.0001$ , NS:  $P > 0.05$ . P values were calculated by Mann-Whitney's U test.

**Figure 2. Selection of autoantibodies of clinical relevance.**

(A) Volcano plot that shows autoantibodies differentially elevated in SSc before treatment compared to HCs. The vertical dash line indicates  $P = 0.05$ . (B) Volcano plot that shows autoantibodies differentially increased in HRs than in LRs. (C) Volcano plot that shows autoantibodies significantly reduced in HRs during RTX therapy. (D) Heat map that shows the serum levels of 58 candidate autoantibodies of clinical relevance. (E) Principal component analysis of 58 candidate autoantibodies of clinical relevance. In the scatter plot, individual subjects as points. The loading diagram illustrates the contributions to PC1 and PC2. (F) SAL focused on 58 candidate autoantibodies of clinical relevance. \*\*\*:  $P < 0.001$ , \*\*\*\*:  $P < 0.0001$ , NS:  $P > 0.05$ . P values were calculated by Mann-Whitney's U test. (G) The receiver-operator characteristics (ROC) curve demonstrating the discrimination between SSc and HCs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow). (H) The ROC curve demonstrating the discrimination between HRs and LRs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow).



**Figure 3. Proteins targeted by the candidate autoantibodies of clinical relevance.**

(A) Gene ontology analysis encompassing the genes coding proteins targeted the candidate autoantibodies. (B) The table represents the inclusion relationship between each gene ontology and the candidate autoantibodies. (C) Serum levels of candidate autoantibodies associated with “import across plasma membrane.” (D) The heatmap illustrates correlation between the candidate autoantibodies associated with “import across plasma membrane” and clinical traits of SSc. (E) Serum levels of autoantibodies associated with “peptide GPCRs.” (F) The heatmap illustrates correlation between the candidate autoantibodies associated with “peptide GPCRs” and clinical traits of SSc. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ . P values were calculated by Spearman’s correlation test.

**Figure 4. WGCNA analysis.** (A) Network heatmap plot. Branches in the hierarchical clustering dendrograms correspond to modules. Color-coded module membership is displayed in the color bars below and to the right of the dendrograms. In the heatmap, high co-expression interconnectedness is indicated by progressively more saturated yellow and red colors. (B) The table represents the inclusion relationship between autoantibodies and modules identified by WGCNA analysis. (C) Gene ontology analysis encompassing the genes coding proteins targeted by autoantibodies included in the “turquoise,” “darkmagenta,” and “tan” modules. (D) The heatmap shows the correlation between each module and clinical trait. \*:  $P < 0.05$ , \*\*:  $P < 0.01$ , \*\*\*:  $P < 0.001$ . P values were calculated by Spearman’s correlation test.






**Extended Figure 1. Additional results of PWAS.** (A) The sum of autoantibody levels (SAL) by age groups. (B) Serum levels of SSc-related autoantibodies before and after the DESIRES trial by the treatment arm and responsiveness.

**Extended Figure 2. Autoantibodies highlighted in each machine learning model.**


(A) Autoantibodies that were mostly highlighted according to feature importance by Lasso regression, Ridge regression, SVM with normalization, Random Forest, XGBoost, and LightGBM. (B) The inclusion relationship of autoantibodies highlighted by the six machine learning frameworks illustrated by an UpSet plot. (C) The box plots describe the serum levels of autoantibodies highlighted by more than two frameworks in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

**Extended Figure 3. Distribution of the candidate autoantibodies among various disorders.** The box plots describe the serum levels of the candidate autoantibodies associated with “import across plasma membrane” (**A**) and “peptide GPCRs” (**B**) in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

**Extended Figure 4. Expression of highlighted autoantigens in human tissues and single cells.** Expression of autoantigens associated with “import across plasma membrane” (**A**) or with “peptide GPCRs” (**B**) in multiple human tissues, as measured by bulk RNA-sequencing from the Human Protein Atlas. Expression of CCR8 (**C**) or FPR1 (**D**) in immune cells from multiple human tissues, as measured by single-cell RNA-sequencing from the Tabula Sapiens project.



Matsuda KM et al.  
Figure 1




Matsuda KM et al.  
Figure 2



**A**





## Gene Ontology Analysis




GO:0098739: import across plasma membrane  
 WP24: Peptide GPCRs  
 GO:0006281: DNA repair  
 GO:1904063: negative regulation of cation transmembrane transport  
 GO:0043467: regulation of generation of precursor metabolites and energy  
 GO:0043484: regulation of RNA splicing  
 R-HSA-112316: Neuronal System

**B**

	PSEN1	SLC22A2	TRPV5	SLC46A1	CCR8	FPR1	MC1R	GPR63
GO:0098739								
WP24								
GO:0006281								
GO:1904063								
GO:0043467								
GO:0043484								
R-HSA-112316								

**C****D****E****F**



Matsuda KM et al.  
 Figure 4